Thus, Cobi+Reg produced marked antitumor efficacy in multiple PDX lines encompassing the major molecular subtypes of melanoma (i.e., BRAF-, NRAS-, and NF-1–mutant) developed after progression on PD-1–based ICB. The gene discussed is BRAF; the disease is melanoma.